ValuEngine downgraded shares of ImmunoGen, Inc. (NASDAQ:IMGN) from a hold rating to a sell rating in a report released on Thursday morning.

A number of other research firms also recently issued reports on IMGN. Cowen and Company restated a hold rating on shares of ImmunoGen in a research report on Tuesday, August 29th. William Blair restated an outperform rating on shares of ImmunoGen in a research report on Monday, June 26th. Cantor Fitzgerald set a $5.00 target price on shares of ImmunoGen and gave the company a hold rating in a research report on Sunday, June 4th. BidaskClub downgraded shares of ImmunoGen from a strong-buy rating to a buy rating in a research report on Wednesday, July 19th. Finally, Zacks Investment Research upgraded shares of ImmunoGen from a hold rating to a buy rating and set a $7.75 target price on the stock in a research report on Tuesday, June 27th. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the stock. The stock currently has a consensus rating of Hold and an average target price of $8.01.

ImmunoGen (IMGN) opened at 6.55 on Thursday. The firm’s market cap is $586.86 million. ImmunoGen has a 52 week low of $1.51 and a 52 week high of $8.84. The stock has a 50 day moving average of $6.59 and a 200 day moving average of $5.25.

ImmunoGen (NASDAQ:IMGN) last released its earnings results on Friday, July 28th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.07. The business had revenue of $39.02 million for the quarter, compared to analyst estimates of $30.59 million. During the same quarter in the previous year, the company posted ($0.53) earnings per share. The business’s revenue for the quarter was up 426.6% on a year-over-year basis. Analysts anticipate that ImmunoGen will post ($0.74) EPS for the current year.

TRADEMARK VIOLATION NOTICE: This news story was originally published by Daily Political and is the sole property of of Daily Political. If you are reading this news story on another site, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be accessed at https://www.dailypolitical.com/2017/09/24/immunogen-inc-imgn-downgraded-to-sell-at-valuengine.html.

In other news, VP Craig Barrows sold 14,600 shares of the company’s stock in a transaction dated Wednesday, September 13th. The stock was sold at an average price of $6.95, for a total value of $101,470.00. Following the completion of the sale, the vice president now directly owns 51,100 shares of the company’s stock, valued at approximately $355,145. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 6.51% of the company’s stock.

Several hedge funds have recently made changes to their positions in IMGN. Teachers Advisors LLC increased its stake in shares of ImmunoGen by 10.6% in the 4th quarter. Teachers Advisors LLC now owns 209,859 shares of the biotechnology company’s stock valued at $428,000 after acquiring an additional 20,171 shares during the last quarter. Acadian Asset Management LLC bought a new stake in shares of ImmunoGen in the 1st quarter valued at about $117,000. Janney Montgomery Scott LLC increased its stake in shares of ImmunoGen by 11.1% in the 1st quarter. Janney Montgomery Scott LLC now owns 58,815 shares of the biotechnology company’s stock valued at $228,000 after acquiring an additional 5,893 shares during the last quarter. Bank of New York Mellon Corp increased its stake in shares of ImmunoGen by 15.4% in the 1st quarter. Bank of New York Mellon Corp now owns 438,917 shares of the biotechnology company’s stock valued at $1,698,000 after acquiring an additional 58,516 shares during the last quarter. Finally, UBS Asset Management Americas Inc. increased its stake in shares of ImmunoGen by 148.6% in the 1st quarter. UBS Asset Management Americas Inc. now owns 68,097 shares of the biotechnology company’s stock valued at $264,000 after acquiring an additional 40,700 shares during the last quarter. 84.64% of the stock is owned by institutional investors.

ImmunoGen Company Profile

ImmunoGen, Inc is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. The Company is engaged in the discovery of monoclonal antibody-based anticancer therapeutics. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for ImmunoGen (NASDAQ:IMGN)

Receive News & Ratings for ImmunoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.